Amyloidosis: Treatment and Management

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Amyloidosis is a serious condition caused by the buildup of abnormal, insoluble amyloid fibrils within the tissues and organs. The two most common forms associated with cardiac complications are immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. Patients may present with heart failure with preserved ejection fraction (HFpEF) or develop restrictive cardiomyopathy, leading to significant functional impairment.

In this CardioBites+ video, we explore the role of disease-modifying treatments as well as non-disease-modifying therapies for patients with cardiac amyloidosis.

Please visit our post-module evaluation survey as well!
Link to survey: https://www.surveymonkey.com/r/8RL5D9K

Visit our website: https://hfsa.org/cardiobitesplus
HFSA LinkedIn: / hfsa
HFSA Twitter: / hfsa
HFSA Learning Center: https://learningcenter.hfsa.org/
Join HFSA to enjoy member benefits: https://hfsa.org/membership/membership-benefits-and-categories
Categoria
Cardiology
Commenta per primo questo video.

Prossimo